Orchestra BioMed Holdings (OBIO) Change in Receivables (2022 - 2026)
Orchestra BioMed Holdings' (OBIO) quarterly Change in Receivables came in at -$11000.0 in Q1 2026, down 266.67% year-on-year from $6600.0 in Q1 2025, and down 125.58% on a QoQ basis from $43000.0 in Q4 2025.
Orchestra BioMed Holdings (OBIO) Change in Receivables (2022 - 2026) Analysis & Trends
Orchestra BioMed Holdings (OBIO) has 5 years of Change in Receivables data on file, last reported at -$11000.0 in Q1 2026.
- On a quarterly basis, Change in Receivables fell 266.67% year-over-year to -$11000.0 in Q1 2026; TTM through Mar 2026 was -$5000.0, a 171.43% decrease from a year earlier, with the FY2025 full-year figure at $3000.0, up 113.64% from the prior year.
- Change in Receivables for Q1 2026 stood at -$11000.0, down from $43000.0 in the prior quarter.
- Over the last five years, Change in Receivables for OBIO reached as high as $95000.0 in Q2 2023 and fell as low as -$85000.0 in Q3 2023.
- Historically, Change in Receivables has averaged -$3250.0 across 5 years, with a median of -$4500.0 in 2025.
- On a YoY basis, Change in Receivables climbed as much as 9400.0% in 2023 and fell as far as 631.25% in 2023.
- Year by year, Change in Receivables stood at $16000.0 in 2022, then decreased by 18.75% to $13000.0 in 2023, then slumped by 392.31% to -$38000.0 in 2024, then surged by 213.16% to $43000.0 in 2025, then tumbled by 125.58% to -$11000.0 in 2026.
- Per Business Quant data, the three most recent Change in Receivables figures were -$11000.0 in Q1 2026, $43000.0 in Q4 2025, and -$31000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 75.30 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | -39.80 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | -1.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Orchestra BioMed Holdings | 235.83 Mn | 141.43 Mn | 78,000.00 | -11,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -11,000.00 |
| Mar 31, 2026 | -11,000.00 |
| Dec 31, 2025 | 43,000.00 |
| Dec 31, 2025 | 43,000.00 |
| Sep 30, 2025 | -31,000.00 |
| Sep 30, 2025 | -31,000.00 |
| Jun 30, 2025 | -6,000.00 |
| Jun 30, 2025 | -6,000.00 |
| Mar 31, 2025 | -3,000.00 |
| Mar 31, 2025 | -3,000.00 |
| Dec 31, 2024 | -38,000.00 |
| Dec 31, 2024 | -38,000.00 |
| Sep 30, 2024 | 35,000.00 |
| Sep 30, 2024 | 35,000.00 |
| Jun 30, 2024 | 13,000.00 |
| Jun 30, 2024 | 13,000.00 |
| Mar 31, 2024 | -32,000.00 |
| Mar 31, 2024 | -32,000.00 |
| Dec 31, 2023 | 13,000.00 |
| Dec 31, 2023 | 13,000.00 |